C_60d Frn

9077

Federal Register / Vol. 86, No. 27 / Thursday, February 11, 2021 / Notices
development, validation, or appropriate
use of innovative Lyme disease
diagnostic tests, and what factors are
most critical to ensure their success?
This information will inform the
development of the HHS Lyme
Innovation initiative and the LymeX
public-private partnership to create
meaningful incentives to develop or
validate new diagnostic tests for Lyme
disease.
Kristen Honey,
Senior Advisor to the Assistant Secretary for
Health (ASH), Office of the Assistant
Secretary for Health, U.S. Department of
Health and Human Service.
[FR Doc. 2021–02796 Filed 2–10–21; 8:45 am]
BILLING CODE 4150–28–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Document Identifier OS–0990–xxxx]

Agency Information Collection
Request. 60-Day Public Comment
Request
Office of the Secretary, HHS.
Notice.

AGENCY:
ACTION:

In compliance with the
requirement of the Paperwork
Reduction Act of 1995, the Office of the
Secretary (OS), Department of Health
and Human Services, is publishing the
following summary of a proposed
collection for public comment.
DATES: Comments on the ICR must be
received on or before April 12, 2021.
ADDRESSES: Submit your comments to
Sherrette.Funn@hhs.gov or by calling
(202) 795–7714.
FOR FURTHER INFORMATION CONTACT:
When submitting comments or
requesting information, please include
the document identifier 0990-New-60D,
and project title for reference, to
Sherrette Funn, Reports Clearance
Officer, Sherrette.funn@hhs.gov, 202–
795–7714.
SUMMARY:

Interested
persons are invited to send comments
regarding this burden estimate or any
other aspect of this collection of
information, including any of the
following subjects: (1) The necessity and
utility of the proposed information
collection for the proper performance of
the agency’s functions; (2) the accuracy
of the estimated burden; (3) ways to
enhance the quality, utility, and clarity
of the information to be collected; and
(4) the use of automated collection
techniques or other forms of information
technology to minimize the information
collection burden.
Title of the Collection: Family
Planning Annual Report 2.0.
Type of Collection: New.
Abstract: The Office of Population
Affairs (OPA), within the Office of the
Assistant Secretary for Health, seeks
approval for a new encounter level data
collection for the Family Planning
Annual Report (FPAR). Currently
collected in aggregate under OMB No.
0990–0221, this new data collection,
‘‘FPAR 2.0’’, will collect information at
the encounter level and build on the
existing data collection and reporting
system. This annual reporting
requirement is for competitively
awarded grants authorized and funded
by the Title X Family Planning Program.
Need and Proposed Use of the
Information: The Office of Population
Affairs’ (OPA) Title X Family Planning
Program is the only federal grant
program dedicated solely to providing
comprehensive family planning and
related preventive health services.
Annual submission of the FPAR is
required of all Title X family planning
services grantees for purposes of
monitoring and reporting program
performance (45 CFR part 74 and 45
CFR part 92). The FPAR is the only
source of annual, uniform reporting by
all grantees funded under Section 1001
of the Title X Public Health Service Act.
Similar to the previous FPAR, FPAR 2.0

SUPPLEMENTARY INFORMATION:

will provide consistent, national-level
data on the Title X Family Planning
program and its users. OPA will be able
to assemble and analyze comparable
and relevant program data to answer
questions about the characteristics of
the population served, the provision
and use of services, and the impact of
the program on certain family planning
outcomes. FPAR 2.0 will also collect a
standard set of data elements pertaining
to users and encounters, such as user
demographics, service delivery, family
planning intentions and methods, and
other indicators, which allow for
comparisons over time at all levels of
the program (e.g., national, regional,
state, and grantee). Encounter level data
collected through FPAR 2.0 will
ultimately improve the quality of data
reported to OPA and reduce reporting
burden by grantees. Additionally, the
more granular data collected with FPAR
2.0 will help contribute to a learning
healthcare environment by greatly
expanding the options for data analysis
and reporting—for example, through
interactive data dashboards and
visualizations, customized tabulations
and reports, and application of analytics
and statistical analyses on the
encounter-level data files.
Information from FPAR 2.0 is
important to OPA for many reasons, and
will be used to:
(1) Monitor compliance with statutory
requirements, regulations, and
operational guidance.
(2) Comply with accountability and
federal performance requirements for
Title X family planning funds.
(3) Guide strategic and financial
planning, to monitor performance, to
respond to inquiries from policymakers
and Congress about the program, and to
estimate program impact.
Type of respondent: Annual reporting;
respondents are all grantees that receive
Title X funding from OPA.

khammond on DSKJM1Z7X2PROD with NOTICES

ANNUALIZED BURDEN HOUR TABLE
Average
burden per
response

Respondents
(if necessary)

FPAR 2.0 ..........................................

Grantees ...........................................

74

1

36

2,664

Total ...........................................

...........................................................

........................

1

........................

2,664

VerDate Sep<11>2014

16:39 Feb 10, 2021

Jkt 253001

PO 00000

Frm 00034

Number of
respondents

Number of
responses per
respondents

Forms
(if necessary)

Fmt 4703

Sfmt 4703

E:\FR\FM\11FEN1.SGM

11FEN1

Total burden
hours

9078

Federal Register / Vol. 86, No. 27 / Thursday, February 11, 2021 / Notices

Sherrette A. Funn,
Office of the Secretary, Paperwork Reduction
Act Reports Clearance Officer.

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

[FR Doc. 2021–02825 Filed 2–10–21; 8:45 am]

National Institutes of Health

BILLING CODE 4150–34–P

National Human Genome Research
Institute; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.

National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting

khammond on DSKJM1Z7X2PROD with NOTICES

Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Board of Scientific
Counselors, National Cancer Institute.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
National Cancer Institute, including
consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors, National Cancer Institute.
Date: March 9, 2021.
Time: 11:00 a.m. to 5:40 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Cancer Institute, Shady
Grove, 9609 Medical Center Drive, Rockville,
MD 20850, (Virtual Meeting).
Contact Person: Brian E. Wojcik, Ph.D.,
Executive Secretary, Institute Review Office,
Office of the Director, National Cancer
Institute, National Institutes of Health, 9609
Medical Center Drive, Room 3W414,
Rockville, MD 20850, 240–276–
5660,wojcikb@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: February 5, 2021.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–02791 Filed 2–10–21; 8:45 am]
BILLING CODE 4140–01–P

VerDate Sep<11>2014

16:39 Feb 10, 2021

Jkt 253001

Name of Committee: National Human
Genome Research Institute Initial Review
Group; Genome Research Review Committee
GNOM.
Date: March 11, 2021.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Greider Conference Room
3189, Bethesda, MD 20892, Telephone: 301–
594–4280, Fax: 301–435–1580, (Virtual
Meeting).
Contact Person: Keith McKenney, Ph.D.
Scientific Review Officer, National Human
Genome Research Institute, National
Institutes of Health, 6700B Rockledge Drive,
Bethesda, MD 20817, 301–594–4280
mckenneyk@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: February 5, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–02784 Filed 2–10–21; 8:45 am]
BILLING CODE 4140–01–P

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Single Cell Mapping Centers and Data
Coordinating Center.
Date: March 18, 2021.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Greider Conference Room
3189, Bethesda, MD 20892, Telephone: 301–
594–4280, Fax: 301–435–1580 (Virtual
Meeting).
Contact Person: Keith McKenney, Ph.D.,
Scientific Review Officer, National Human
Genome Research Institute, National
Institutes of Health, 6700B Rockledge Drive,
Bethesda, MD 20817 301–594–4280,
mckenneyk@mail.nih.gov.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Predictive Modeling—SEP.
Date: March 23, 2021.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Greider Conference Room
3189, Bethesda, MD 20892, Telephone: 301–
594–4280, Fax: 301–435–1580 (Virtual
Meeting).
Contact Person: Keith McKenney, Ph.D.,
Scientific Review Officer, National Human
Genome Research Institute, National
Institutes of Health, 6700B Rockledge Drive,
Bethesda, MD 20817 301–594–4280
mckenneyk@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: February 5, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–02787 Filed 2–10–21; 8:45 am]

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections

PO 00000

Frm 00035

Fmt 4703

Sfmt 4703

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.

E:\FR\FM\11FEN1.SGM

11FEN1